Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Evaluation of Immune Status in Tumor Patients-Reply

Evaluation of Immune Status in Tumor Patients-Reply This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables. Abstract To the Editor.–An accurate immunologic staging procedure would be of great usefulness in determining prognosis and therapy for the cancer patient, and perhaps such staging will be possible at some future time. We would question the usefulness of the scheme proposed by Guinan et al for several reasons. The role of blocking or enhancement type antibodies in impeding immune responsiveness has not been defined. There is no solid evidence that establishes the role of IgG or IgM in tumor control. A general state of anergy or diminished dermal responsiveness to ubiquitous antigens is associated with diminished responsiveness of lymphocytes in culture to nonspecific mitogens, and this in our experience correlates with an unfavorable clinical course in the patient. It may be premature, however, to embark on a scheme for the clinical immune staging of cancer patients when the precise role of specific blocking factors, IgG and IgM, nonspecific http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Evaluation of Immune Status in Tumor Patients-Reply

Archives of Surgery , Volume 109 (5) – Nov 1, 1974

Evaluation of Immune Status in Tumor Patients-Reply

Abstract

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables. Abstract To the Editor.–An accurate immunologic staging procedure would be of great usefulness in determining prognosis and therapy for the cancer patient, and perhaps such staging will be possible at some future time. We would question the usefulness of the scheme proposed by Guinan et al for several reasons. The role of blocking or enhancement type...
Loading next page...
 
/lp/american-medical-association/evaluation-of-immune-status-in-tumor-patients-reply-oNzkUnzlvb
Publisher
American Medical Association
Copyright
Copyright © 1974 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1974.01360050112025
Publisher site
See Article on Publisher Site

Abstract

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables. Abstract To the Editor.–An accurate immunologic staging procedure would be of great usefulness in determining prognosis and therapy for the cancer patient, and perhaps such staging will be possible at some future time. We would question the usefulness of the scheme proposed by Guinan et al for several reasons. The role of blocking or enhancement type antibodies in impeding immune responsiveness has not been defined. There is no solid evidence that establishes the role of IgG or IgM in tumor control. A general state of anergy or diminished dermal responsiveness to ubiquitous antigens is associated with diminished responsiveness of lymphocytes in culture to nonspecific mitogens, and this in our experience correlates with an unfavorable clinical course in the patient. It may be premature, however, to embark on a scheme for the clinical immune staging of cancer patients when the precise role of specific blocking factors, IgG and IgM, nonspecific

Journal

Archives of SurgeryAmerican Medical Association

Published: Nov 1, 1974

There are no references for this article.